Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
0(0%)
Results Posted
88%(7 trials)
Terminated
1(11%)

Phase Distribution

Ph early_phase_1
1
11%
Ph phase_2
1
11%
Ph phase_4
1
11%
Ph phase_3
5
56%
Ph phase_1
1
11%

Phase Distribution

2

Early Stage

1

Mid Stage

6

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
1(11.1%)
Phase 3Large-scale testing
5(55.6%)
Phase 4Post-market surveillance
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(8)
Terminated(1)

Detailed Status

Completed8
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (11.1%)
Phase 11 (11.1%)
Phase 21 (11.1%)
Phase 35 (55.6%)
Phase 41 (11.1%)

Trials by Status

completed889%
terminated111%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_3

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age

NCT01621802
completedphase_3

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)

NCT01341639
completedearly_phase_1

Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant

NCT02687763
completedphase_4

Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)

NCT00326183
completedphase_2

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

NCT00578175
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT01621802Phase 3

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age

Completed
NCT01341639Phase 3

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)

Completed
NCT02687763Early Phase 1

Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant

Completed
NCT00326183Phase 4

Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)

Completed
NCT00578175Phase 2

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

Completed
NCT00402831Phase 3

ProQuad® Intramuscular vs Subcutaneous

Completed
NCT00432042Phase 3

Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)

Completed
NCT00560755Phase 3

Safety Study of ProQuad® rHA in Infants (V221-037)

Completed
NCT00258726Phase 1

Immune Responses to Two Dose Varivax +/- MMR-II

Terminated

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9